Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ADGRL3	rs6551665	AG + GG	methylphenidate	efficacy	no	Assessed as haplotype block as rs6551665 and rs1947275. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The GT/GT haplotype had faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. GG has faster response compared to AG.	Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	25989180	1447964201
ADGRL3	rs1947275	CT + TT	methylphenidate	efficacy	no	Assessed as haplotype block as rs6551665 and rs1947275. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The GT/GT haplotype had faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. GT/GT has faster response compared to GT/AC.	Genotypes CT + TT are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype CC.	25989180	1447964243
ADGRL3	rs6813183	CC + CG	methylphenidate	efficacy	yes	Assessed as haplotype block as rs6813183, rs1355368, and rs734644. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The CGC/CGC diplotype showed faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. CGC/CGC has faster response compared to CGC/GAT.	Genotypes CC + CG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype GG.	25989180	1447964257
ADGRL3	rs734644	CC + CT	methylphenidate	efficacy	yes	Assessed as haplotype block as rs6813183, rs1355368, and rs734644. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The CGC/CGC diplotype showed faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. CGC/CGC has faster response compared to CGC/GAT.	Genotypes CC + CT are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype TT.	25989180	1447964285
ADGRL3	rs6551665	A	methylphenidate	efficacy	no		Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.	29230023	1450180321
ADGRL3	rs1947274	A	methylphenidate	efficacy	no		Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	29230023	1450180328
ADGRL3	rs1868790	AA	methylphenidate	efficacy	yes	For the genetic component, in the CGI-S model, a recessive effects for ADGRL3 rs1868790 was found, which was associated with significant impairment. Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS). Note the article only states the association of AA in a recessive model without referring to the compared allele. dbSNP references the rsID as T>G and T>A change.	Genotype AA is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AT + TT.	28871191	1450376553
ADGRL3	rs6858066	G	methylphenidate	efficacy	no	Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	28871191	1450376560
ADGRL3	rs6551665	G	methylphenidate	efficacy	no	Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	28871191	1450376612
ADGRL3	rs6813183	G	methylphenidate	efficacy	no	Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	28871191	1450376618
ADGRL3	rs1947274	C	methylphenidate	efficacy	not stated	RAST inattention scores and the RAST hyperactivity scores are used as response measure. Genetic associations under the additive mode of inheritance. An odds ratio smaller than one means that the higher the minor allele count for that SNP, the more likely the corresponding subject will be non-responder.	Allele C is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	22851411	1450376831
ADGRL3	rs2345039	G	methylphenidate	efficacy	not stated	RAST inattention scores and the RAST hyperactivity scores are used as response measure. Genetic associations under the additive mode of inheritance. An odds ratio smaller than one means that the higher the minor allele count for that SNP, the more likely the corresponding subject will be non-responder.	Allele G is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	22851411	1450376837
ADGRL3	rs6858066	G	methylphenidate	efficacy	not stated	RAST inattention scores and the RAST hyperactivity scores are used as response measure. Genetic associations under the additive mode of inheritance. An odds greater than one means that the higher the minor allele count fort hat SNP, the more likely the corresponding subject will be a mixed (respectively mild-good and good) responder.	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	22851411	1450376843
ADGRL3	rs6551665	G	methylphenidate	efficacy	not stated	For treatment response, the risk haplotype AAG for 6551665-rs1947274-rs6858066 was associated with poor treatment response, while children having the GCA haplotype improved with treatment, as measured by the CGI-overall improvement scale. Study doesnt report number of subjects or p-values.	Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	22486528	1450376849
ADGRL3	rs1947274	C	methylphenidate	efficacy	not stated	For treatment response, the risk haplotype AAG for 6551665-rs1947274-rs6858066 was associated with poor treatment response, while children having the GCA haplotype improved with treatment, as measured by the CGI-overall improvement scale. Study doesnt report number of subjects or p-values.	Allele C is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	22486528	1450376858
ADGRL3	rs6858066	A	methylphenidate	efficacy	not stated	For treatment response, the risk haplotype AAG for 6551665-rs1947274-rs6858066 was associated with poor treatment response, while children having the GCA haplotype improved with treatment, as measured by the CGI-overall improvement scale. Study doesnt report number of subjects or p-values.	Allele A is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.	22486528	1450376864
ADGRL3	rs6551665	G	methylphenidate	efficacy	no	The study defined a good response group as those for whom the K-ARS score at 8 weeks of trial was more than 50% lower than the baseline scores. A secondary efficacy measure was defined as CGI-I score at 8 weeks of 1 or 2. None of the SNPs was associated with OROS MPH treatment response.	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	25229170	1450376870
ADGRL3	rs2345039	G	methylphenidate	efficacy	no	The study defined a good response group as those for whom the K-ARS score at 8 weeks of trial was more than 50% lower than the baseline scores. A secondary efficacy measure was defined as CGI-I score at 8 weeks of 1 or 2. None of the SNPs was associated with OROS MPH treatment response.	Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.	25229170	1450376877
ADGRL3	rs1947274	C	methylphenidate	efficacy	no	The study defined a good response group as those for whom the K-ARS score at 8 weeks of trial was more than 50% lower than the baseline scores. A secondary efficacy measure was defined as CGI-I score at 8 weeks of 1 or 2. None of the SNPs was associated with OROS MPH treatment response.	Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	25229170	1450376883
ADGRL3	rs6551665	AG + GG	methylphenidate	efficacy	not stated	Strengths and Weaknesses of ADHD-Symptoms and Normal-Behavior (SWAN) Scale. Significant positive genotype effects were identified for the Inattention dimension (P=0.02646) but not for the H/I dimension (P=0.09726).	Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	20157310	1450376929
ADGRL3	rs6551665	G	methylphenidate	efficacy	not stated	RAST inattention scores and the RAST hyperactivity scores are used as response measure. Genetic associations under the additive mode of inheritance. An odds ratio smaller than one means that the higher the minor allele count for that SNP, the more likely the corresponding subject will be non-responder.	Allele G is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.	22851411	1450376824
ADGRL3	rs1355368	AG + GG	methylphenidate	efficacy	yes	Assessed as haplotype block as rs6813183, rs1355368, and rs734644. Efficacy measured with parent-rated Swanson, Nolan, and Pelham Scale - version IV, applied at baseline, after 1 month, and after 3 months treatment. Mean dose was 0.60 +/- 0.17 mg/kg/day. Only 4.7% of patients received concomitant medication. The CGC/CGC diplotype showed faster response to treatment, showing better response at 1 month treatment, but the test did not survive multiple test correction and response overall was equal after 3 months. CGC/CGC has faster response compared to CGC/GAT.	Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.	25989180	1447964271